Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice

Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice

<i>Background and objectives:</i> The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient charac...

Full description

Bibliographic Details
Main Authors:	Cristina Galache Osuna, Borja Gómez-Vila, Javier Aubán Pariente, Beatriz Vázquez Losada, Celia Gómez de Castro, Sheila Requena López, Álvaro de Dios Velázquez, Laura Palacios García, Lucía Ordoñez Fernández, Santiago Gómez Diez, Francisco Vázquez López, Jorge Santos-Juanes
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Medicina
Subjects:	psoriasis biological treatment ustekinumab interleukin drug survival
Online Access:	https://www.mdpi.com/1010-660X/56/11/584

Similar Items

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
by: Maeve Lynch, MD, MBBChBAO, et al.
Published: (2017-05-01)

Changes in metabolic parameters in psoriasis patients treated with interleukin-12/23 blockade (ustekinumab)
by: Chau Yee Ng, et al.
Published: (2020-01-01)

Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
by: I. V. Rychkova, et al.
Published: (2019-08-01)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
by: Amy J. Petty, BS, et al.
Published: (2020-08-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017-09-01)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017-03-01)

Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
by: Chiharu Tateishi,, et al.
Published: (2015-07-01)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
by: Martina Burlando, MD, et al.
Published: (2020-05-01)

Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019-04-01)

Effectiveness of resuming ustekinumab therapy in psoriasis patients with metabolic disorders. Clinical experience
by: I. V. Rychkova, et al.
Published: (2019-02-01)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018-10-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Efficacy and safety of ustekinumab in adolescents
by: Kellen R, et al.
Published: (2016-09-01)

The use of ustekinumab in patients with psoriasis and coexisting renal or hepatic dysfunction – a report of two cases
by: Hubert Arasiewicz, et al.
Published: (2014-10-01)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
by: Rosita Saraceno, et al.
Published: (2013-09-01)

Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
by: Beltammer Belkais, et al.
Published: (2019-03-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
by: Martina Burlando, et al.
Published: (2021-04-01)

Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis
by: Misbah N. Ghazanfar, et al.
Published: (2019-07-01)

Late reaction to ustekinumab infusion
by: Marina Resener Morais, et al.
Published: (2013-09-01)

Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings
by: Ana M. Ramos-Leví, et al.
Published: (2018-03-01)

The combined using of ustekinumab and narrow-band phototherapy in treatment of severe psoriasis
by: Kruglova L.S., et al.
Published: (2015-09-01)

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)
by: P. A. Makarchuk, et al.
Published: (2020-10-01)

RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
by: Yu. L. Korsakova, et al.
Published: (2015-04-01)

Ankilozan Spondilit, Crohn Hastalığı ve Anti-tümör Nekroz Faktör-alfa Tedavi ile İndüklenen Psoriasis olan Hastada Ustekinumab Tedavisine Dramatik Yanıt
by: Sevilay Kılıç, et al.
Published: (2020-12-01)

Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis
by: Inês Raposo, et al.
Published: (2019-03-01)

Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data
by: Manuel David Gil-Sierra, et al.
Published: (2020-09-01)

Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab
by: S. Signa, et al.
Published: (2019-07-01)

A case report of heart failure after therapy with ustekinumab
by: Kourosh Beroukhim, et al.
Published: (2015-07-01)

Ustekinumab-induced fixed drug eruption
by: Dhafer M. Hafez, MD, et al.
Published: (2020-12-01)

Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab
by: Jochen H. Hoffmann, et al.
Published: (2017-03-01)

Sarcoid- like Phenomenon - ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature
by: Mohamed M. Gad, et al.
Published: (2019-07-01)

The cost of biologics for psoriasis is increasing
by: Judy Cheng, et al.
Published: (2014-12-01)

Characteristics of patients with psoriatic arthritis treated with ustekinumab. Evidence from real-life clinical practice
by: Yu. L. Korsakova, et al.
Published: (2021-01-01)

Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1–3 genes
by: Beniamin Grabarek, et al.
Published: (2020-01-01)

Generalised pustular psoriasis – a case report and review of therapeutic approaches
by: Agnieszka Osmola-Mańkowska
Published: (2014-11-01)

Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01)

Comparative Evaluation of the Treatment Efficacy and Safety of TNFα and IL12/23 Inhibitors in Children With Psoriasis
by: Nikolay N. Murashkin, et al.
Published: (2019-02-01)

Cannot write session to /tmp/vufind_sessions/sess_0ft6mpmq53pkit459h06ip2278